Study to Assess the Inhibition of Plaque Formation in Subjects With a Gingival Index ≤1.5

Randomized, Placebo-controlled, Parallel Group, Double-blind, Multi-center Phase III Study to Assess the Inhibition of Plaque Formation of 0.1% Octenidine Mouthwash vs Placebo in Subjects With a Gingival Index ≤1.5

The objective of the study is to demonstrate the superiority of 0.1% octenidine mouthwash (Octenidin Mundspüllösung, OML) to placebo (PLAC) in the inhibition of plaque formation. The study will consist of a 14-day screening period and a 5-day treatment period.

Study Overview

• Status: Completed
• Conditions: Inhibition of Plaque Formation (by Gingivitis-Index ≤1.5)
• Intervention / Treatment: Drug: Octenidinedihydrochlorid; Other: Placebo

• Study Type: Interventional
• Enrollment (Actual): 100
• Phase: Phase 3

Contacts and Locations

Study Locations

• Germany
  • Hesse
    • Frankfurt am Main, Hesse, Germany, 60596
      • Poliklinik für Parodontologie der Johann Wolfgang Goethe Universität Frankfurt am Main
  • Saxony
    • Dresden, Saxony, Germany, 01307
      • Poliklinik für Parodontologie der Med. Fakultät C. G. Carus der TU Dresden
    • Leipzig, Saxony, Germany, 04103
      • Poliklinik für Zahnerhaltung und Parodontologie am Universitätsklinikum Leipzig

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 99 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Adult male and female subjects (aged 18 and older);
2. Subjects with a total mean gingival index1 (GI, Löe, 1967) ≤1.5 (0.0-1.5);
3. Subjects with at least 20 teeth (excluding wisdom teeth) with complete natural "Ramfjord-teeth" or their replacement teeth and 10 natural anterior teeth (excluding teeth provided with prosthetics such as crowns, dental bridges, veneers or large vestibular fillings such as large cervical or frontal teeth fillings; teeth with small interdental and orally oriented fillings are allowed);
4. Non-pigmented gingiva;
5. Signed informed consent.

Exclusion Criteria:

1. Subjects with severe systemic diseases (e.g. hepatitis, human immunodeficiency virus [HIV] infection, tuberculosis, acute cancer treatment);
2. Subjects who require endocarditis prophylaxis for dental examination and treatment;
3. Subjects with caries requiring treatment (e.g. caries with cavity) or other oral diseases (including gingival hyperplasia, diseases of the oral mucosa);
4. Subjects who have a history of chronic or aggressive periodontitis;
5. Subjects with current moderate or severe chronic or aggressive periodontitis (periodontal screening index [PSI] >2 in more than 2 sextants or PSI >3);
6. Subjects showing a GI score of 3 on at least one tooth;
7. Subjects who underwent oral surgery within 14 days prior to Screening;
8. Subjects who used antiseptic mouth rinse within 14 days prior to Screening;
9. Subjects wearing orthodontic appliances and removable dentures (Wire-retainers after orthodontic treatment are allowed);
10. Subjects treated with antibiotics less than 3 months prior to the baseline examination at Visit 1 and/or planning such treatment for the duration of the study;
11. Subjects treated with systemically acting corticosteroids or corticosteroids applied via the oral cavity (e.g. asthma sprays);
12. Subjects who suffer from xerostomia;
13. Subjects who have a known hypersensitivity or allergy to the test product and its ingredients or to medications that have a similar chemical structure;
14. Participation of the subject in another clinical study within the last 4 weeks before enrolment in and during this study;
15. Incapability of assessing essence and possible consequences of the study (e.g. alcoholism);
16. Pregnant or breastfeeding women;

17. Women with childbearing potential except those who fulfill one of the following criteria:

    1. Post-menopausal (12 months of natural amenorrhea or 6 months of amenorrhea with serum follicle-stimulating hormone [FSH] >40 U/ml);
    2. Postoperative (6 weeks after bilateral ovariectomy with or without hysterectomy);
    3. Continuous and correct application of a highly effective contraception method with a Pearl Index <1% (e.g. implants, depots, oral contraceptives, intrauterine device [IUD]);
    4. Sexual abstinence; whereas sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject;
    5. Confirmation of vasectomy of the sexual partner;
18. Evidence suggesting that the subject is not likely to follow the study protocol (e.g. lacking compliance).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Octenidine Mouthwash; 0.1% Octenidinedihydrochlorid Solution for oromucosal use, mouth rinse with 10 ml for 30 s, 10 applications over 5 days	Drug: Octenidinedihydrochlorid; Mouth rinsing of the oral cavity with Octenidinehydrochlorid vs.Placebo over a period of 5 days; Other Names: 0.1% Octenidine Mouthwash; OML
Placebo Comparator: Placebo; Placebo Solution for oromucosal use, mouth rinse with 10 ml for 30 s, 10 applications over 5 days	Other: Placebo; Mouth rinsing of the oral cavity with Octenidinehydrochlorid vs.Placebo over a period of 5 days

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Total mean PI (Plaque index according to Silness and Löe) after 5 days of treatment at Visit 2	The total mean PI is the sum of the individual scores divided by the number of investigated sites. The thickness and extension of plaque along the gingival margin will be assessed.	after 5 days of treatment

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Bacterial count reduction in saliva after a single administration of OML vs placebo	Bacterial count in saliva will be assessed prior to the first administration of study medication and 1 min after the first administration	after 1 minute of rinsing
Change in total mean GI (Gingival Index according to Löe, 1967) from Visit 1 to Visit 2	The total mean GI is the sum of the individual scores divided by the number of investigated sites. The GI for each tooth is the sum of the 4 individual scores divided by 4.	baseline and after 5 days of treatment
Incidence and severity of AEs (adverse events)		5 days
Incidence of SAEs (serious adverse events)		15 days
Change in tooth discoloration index from Visit 1 to Visit 2		baseline and after 5 days of treatment

Collaborators and Investigators

• Sponsor: Schülke & Mayr GmbH
• Investigators: Principal Investigator: Katrin Lorenz, Dr.med.dent., Med. Fakultät C. G. Carus der TU Dresden, Poliklinik für Parodontologie

Study record dates

Study Major Dates

• Study Start (Actual): January 22, 2018
• Primary Completion (Actual): December 14, 2018
• Study Completion (Actual): December 14, 2018

Study Registration Dates

• First Submitted: October 23, 2017
• First Submitted That Met QC Criteria: October 23, 2017
• First Posted (Actual): October 26, 2017

Study Record Updates

• Last Update Posted (Actual): January 22, 2019
• Last Update Submitted That Met QC Criteria: January 18, 2019
• Last Verified: January 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Infections; Stomatognathic Diseases; Periodontal Diseases; Mouth Diseases; Gingival Diseases; Gingivitis; Anti-Infective Agents, Local; Anti-Infective Agents; Octenidine
• Other Study ID Numbers: OML-III-A; 2017-001697-42 (EudraCT Number)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No